A system for producing pharmaceutical objects, such as tablets, granules and capsules, via 3D printing. The system comprises a 3D printing machine (2) with a mechanical system (3) movable in one or more directions, at least one print head (5) with a nozzle (37) being movable by the mechanical system and a base system (4) carrying a print base (6) for receiving a prepared mixture (27) applied by the print head (5). The system comprises at least one carrier (35) for holding a cartridge (28). Printing is done at formatted print locations (49) on the base (6). A method for producing pharmaceutical objects by providing at least one pharmaceutical substance in at least one cartridge, placing the cartridge in a carrier, establishing a fluid connection between a cartridge and a print head, moving the print head nozzle according to a program and dispensing the pharmaceutical substance to a print base.

The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.

The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.

A method and system for assembling sets of medical instruments and/or pharmaceutical products. The system includes a control system comprising or being connected to a database comprising data objects corresponding to available objects. An input area is provided to receive batches of unsorted medical instruments or pharmaceutical product containers, and an identification area having an identification unit. A temporary sorting area is also provided, including a plurality of storage positions provided with visual indications capable of visually indicating one of the storage position at a time, and an output area, possibly being overlapping with the input area, arranged to receive medical instruments and/or pharmaceutical products as assembled sets. The controller is arranged to receive information from the identification unit obtained when an item is arranged on the identification area, and to identify the item in the database.

A method and system for assembling sets of medical instruments and/or pharmaceutical products. The system includes a control system comprising or being connected to a database comprising data objects corresponding to available objects. An input area is provided to receive batches of unsorted medical instruments or pharmaceutical product containers, and an identification area having an identification unit. A temporary sorting area is also provided, including a plurality of storage positions provided with visual indications capable of visually indicating one of the storage position at a time, and an output area, possibly being overlapping with the input area, arranged to receive medical instruments and/or pharmaceutical products as assembled sets. The controller is arranged to receive information from the identification unit obtained when an item is arranged on the identification area, and to identify the item in the database.

A solid dosage product having a tailored dissolution profile comprises a carrier block defining a plurality of compartments where each respective compartment is configured to receive one or more active pharmaceutical ingredient and the carrier block being digestible within an animal such that each respective active pharmaceutical ingredient is controllably released; and one or more coating layers applied to the carrier block. A method for manufacturing a solid dosage product having a tailored dissolution comprises manufacturing a digestible carrier block where the carrier block defines a plurality of compartments with each respective compartment configured to receive an active pharmaceutical ingredient; filling a respective compartment with a respective active pharmaceutical ingredient; and coating the carrier block with one or more coating layers.

Provided is a method for determining the genuineness or spuriousness of a pharmaceutical composition for oral administration, comprising irradiating a pharmaceutical composition for oral administration with infrared light, the pharmaceutical composition for oral administration being marked with a mark including an edible substance which is visually recognizable under white light irradiation as well as under infrared irradiation and a mark including an edible substance which is visually recognizable under white light irradiation and is not visually recognizable under infrared irradiation, and determining whether a visually recognizable mark visually recognized on the pharmaceutical composition for oral administration irradiated with the infrared light and a prepared reference mark match.

The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,-2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.

The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,-2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.